MENUNews Archive
Date: 03/29/2023
Using artificial intelligence, researchers have discovered how to screen for genetic mutations in cancerous brain tumors in under 90 seconds — and possibly streamline the diagnosis and treatment of gliomas, a study suggests.
Date: 03/27/2023
Maria G. Castro, Ph.D., R. C. Schneider Collegiate Professor of Neurosurgery and professor of cell and developmental biology at the University of Michigan, was inducted to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.
Date: 02/27/2023
Paul Swiecicki, M.D., has been named the inaugural associate medical director for the Oncology Clinical Trials Support Unit at the Rogel Cancer Center. The appointment was effective Jan. 1, 2023.
Date: 02/27/2023
Diversity, equity, inclusion and justice are a crucial part of the Rogel Cancer Center’s mission, from Community Outreach and Engagement programs addressing health care disparities to hiring processes and leadership development. Now, diversity is a new requirement from the National Cancer Institute for its Cancer Center Support Grants, a chapter they refer to as the Plan to Enhance Diversity. In submitting the CCSG renewal last year, Rogel leadership provided a detailed outline of how we will support a diverse workforce.
Date: 02/23/2023
Russell Ryan, M.D., an assistant professor in the Department of Pathology at the University of Michigan Medical School and a member of the University of Michigan Health Rogel Cancer Center, and his team used a method called ChIP-Seq to map the regulatory elements that control gene expression in B-cell lymphomas, a cancer of the immune system, in sample B-cell cancer cell lines.
Date: 02/20/2023
Research from the University of Michigan Rogel Cancer Center reveals that the metabolic pathways that make a specific type of T cell function are different than previously believed. The key to this discovery lies in a new methodology developed by Hanna Hong, graduate student in immunology and first author of this study.
Date: 02/13/2023
The protein STAT5 has long been an appealing target against cancer, but after decades of research it was consigned to the “undruggable” category. Now, University of Michigan Rogel Cancer Center researchers have found success with a new approach. By tapping into a cellular garbage disposal function, researchers found they could eliminate STAT5 from cell cultures and mice, setting the stage for potential development as a cancer treatment.
Date: 02/08/2023
Starting this month, the University of Michigan Health Ypsilanti Health Center will be offering onsite mammography screening services through a new mobile mammography unit. This addition to the organization’s ambulatory care services will increase access to cancer care and provide screening opportunities for patients near their homes.
Date: 02/02/2023
Researchers at Baylor College of Medicine, the University of Michigan and collaborating institutions working with animal models of GVHD report that alterations in the gut microbiome are connected to an increase in the oxygen levels in the intestine that follows immune-mediated intestinal damage.
Date: 02/02/2023
When noninvasive sound waves break apart tumors, they trigger an immune response in mice. By breaking down the cell wall “cloak,” the treatment exposes cancer cell markers that had previously been hidden from the body’s defenses, researchers at the University of Michigan have shown. The technique developed at Michigan, known as histotripsy, offers a two-prong approach to attacking cancers: the physical destruction of tumors via sound waves and the kickstarting of the body’s immune response. The research shows the potential for this to become a treatment option for patients without the harmful side effects of radiation and chemotherapy.